Farnesoid X receptor agonists for primary biliary cirrhosis

  title={Farnesoid X receptor agonists for primary biliary cirrhosis},
  author={Keith D. Lindor},
  journal={Current Opinion in Gastroenterology},
  • K. Lindor
  • Published 1 May 2011
  • Medicine, Biology
  • Current Opinion in Gastroenterology
Purpose of review This review will provide an overview of the role of nuclear receptors in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic use in cholestatic liver diseases. Recent findings Nuclear receptors have emerged as important mediators of a variety of metabolic and transport functions involving the liver. The role of FXR, in particular, has come to light because of its important role in bile acid homeostasis. The use of potent FXR… 

Pleiotropic functions of bile acids mediated by the farnesoid X receptor.

During a phase II clinical trial, the administration of a semisynthetic BA derivative 6-ethyl-chenodeoxycholic acid to patients with diabetes, non-alcoholic fatty liver disease (NAFLD), led to encouraging results, despite side effects being observed in pre-clinical studies.

Update on FXR Biology: Promising Therapeutic Target?

  • Chang Yeob Han
  • Biology, Medicine
    International journal of molecular sciences
  • 2018
The current knowledge of systemic FXR biology in various organs and the gut–liver axis is summarized, particularly regarding the recent advancement in these fields, and pharmacological aspects of FXR modulation for rational therapeutic strategies and novel drug development are provided.

Obeticholic acid for the treatment of primary biliary cirrhosis

OCA in combination with UDCA leads to significant improvement in liver biochemistries shown to predict outcomes in PBC patients with an incomplete response to UDCA, and long-term efficacy of OCA and its efficacy in patients with advanced PBC need to be delineated.

The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives

An overview of the current knowledge about the use of obeticholic acid in the field of nonviral chronic liver diseases is provided to give a global point of view using a translational approach.

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection

  • C. Bowlus
  • Medicine, Biology
    Hepatic medicine : evidence and research
  • 2016
A series of clinical trials of OCA in PBC have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect.

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of

Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis

Four individuals from two unrelated families with neonatal cholestasis and mutations in NR1H4, which encodes the farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor that regulates bile acids metabolism are reported, demonstrating a pivotal function for FXR in bile Acid homeostasis and liver protection.

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid

Currently, liver transplantation is the most effective treatment modality for PBC patients with end-stage liver disease, and obeticholic acid was approved in 2016 for treatment of patients with PBC with a suboptimal response or intolerance to UDCA.



Nuclear receptors as therapeutic targets in cholestatic liver diseases

The current knowledge on nuclear receptors and their potential role in the treatment of cholestatic liver diseases is reviewed and specific and potent agonists may further enhance the hepatic defence against toxic bile acids.

Pregnane X Receptor Is a Target of Farnesoid X Receptor*

It is demonstrated that the expression of PXR is regulated by farnesoid X receptor, and the combination of the two mechanisms leads to an efficient protection of the liver against bile acid induced toxicity.

Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.

Alterations of hepatobiliary transporters and enzymes are not only relevant for a better understanding of the pathophysiology of cholestatic liver diseases, but may also represent important targets for pharmacotherapy.

Role of bile acids and bile acid receptors in metabolic regulation.

Results suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes.

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

It is established that FXR ligands might represent a novel therapeutic option to treat liver fibrosis and that SHP binds JunD and inhibits DNA binding of adaptor protein (AP)-1 induced by thrombin.

Farnesoid X receptor is essential for normal glucose homeostasis.

A link between lipid and glucose metabolism mediated by the FXR-SHP cascade is identified, and bile acid activation of FXR in WT mice repressed expression of gluconeogenic genes and decreased serum glucose.

Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor γ Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis

It is demonstrated that FXR ligands up-regulate PPARγ mRNA in HSCs and in rodent models of liver fibrosis, indicating that a FXR-PPARγ cascade exerts counter-regulatory effects in H SCs activation.

Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics

The great variety of bile acids and bile alcohols that are present in vertebrates are tabulated and signaling molecules, activating nuclear receptors in the hepatocyte and ileal enterocyte, as well as an increasing number of G-protein coupled receptors are identified.